Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
The aggregate market capitalisation of the 20 largest drugmakers grew by 2% overall to reach $4.3tn. Among these, Bristol ...
Watch out, Gilead and Novartis: there's a new CAR-T in town ... U.K. site dubbed “the Nucleus” with Cardinal Health serving as the U.S. commercial distribution partner. The company has wrapped up all ...